Dental News - Chinese herb may provide relief for autoimmune disorders

Dental Tribune International

Thu. 16 February 2012

save

BOSTON, Mass., USA: Researchers from the Harvard School of Medicine have discovered that a chemical compound found in a traditional Chinese root extract affects autoimmunity by preventing a harmful class of immune cells from developing.

Dichroa febrifuga, commonly known as chang shan, is one of the 50 fundamental herbs of traditional Chinese medicine and has been used as a malarial agent for more than 2,000 years. In the course of a study, Malcolm Whitman, Professor of Developmental Biology at Harvard School of Medicine, and his colleagues found that halofuginone (HF), a natural quinazolinone alkaloid occurring in the herb could be used to treat autoimmune disorders.

Their findings about the small-molecule compound could also be relevant for dental autoimmune immune disorders, such as chronic ulcerative stomatitis. U.S. researchers found in 2011 that painful oral lesions associated with the disease are most likely caused by an autoimmune response.

Earlier studies conducted by Whitman's team in 2009 had already demonstrated that HF activates a response pathway that blocks the development of harmful T helper 17 cells (Th17), which play a key role in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, and that in this regard HF is very selective in its effect. A series of experiments demonstrated that HF inhibits the development of Th17 cells, but does not affect other kinds of T-cells involved in regular immune function.

HF acts by triggering a biochemical pathway known as amino-acid starvation response (ARR), which typically prevents cells from forming when amino acids are in short supply. By depleting amino acids, researchers were able to induce ARR and inhibit differentiation of Th17 cells.

In the current study, Whitman's research team investigated how HF activates the AAR pathway by looking at the most basic process that cells use to translate DNA into the amino-acid chain that makes up a protein. Experiments demonstrated that HF targets a particular enzyme that incorporates the amino acid proline into proteins. It was observed that whenever proline was in short supply, ARR kicked in and produced the therapeutic effects of HF treatment.

According to Whitman, "This compound could inspire novel therapeutic approaches to a variety of autoimmune disorders."

With regard to the treatment of autoimmune disorders, the challenge has been suppressing inflammatory attacks by the immune system on body tissue without generally suppressing immune function. In instances of chronic ulcerative stomatitis, treatment was only successful using hydroxychloroquine, a prescription drug primarily used to prevent malaria and rheumatoid arthritis.

"This study is an existing example of how solving the molecular mechanism of traditional herbal medicine can lead both to new insights into physiological regulation and to novel approaches to the treatment of diseases," said Tracy Kelly, an instructor in Whitman's lab.

However, researchers do not yet fully understand the role that amino-acid limitation plays in disease response or why restricting proline inhibits Th17 cell production.

To post a reply please login or register

Apply for CARES Act Provider Relief Funds by Sept. 13

Dentists have through Sept. 13 to apply for pandemic relief grants through the Department of Health and Human Services’ Enhanced Provider Relief Fund ...

Henry Schein provides health care products for relief after flooding in Pakistan

MELVILLE, NY, USA: Henry Schein, Inc. (Nasdaq: HSIC), is working with its non-governmental organization (NGO) partners—Direct Relief, International ...

Webinar provides tips for day-to-day restorative dentistry

LEIPZIG, Germany: On Feb. 13, the Dental Tribune Study Club will be presenting a new webinar. In the free online course, Dr. Ron Kaminer, an international ...

New remineralisation product may provide a long-term solution for dentine hypersensitivity

SEATTLE, US: Existing treatments for dentine hypersensitivity, including desensitisers and dentinal tubule blockers, offer only temporary relief for ...

Dentists treat patients for sleep disorders

NEW YORK, N.Y., USA: Sleep dentistry is changing the way patients with sleep disorders are treated. Traditionally, sleep apnoea has been the exclusive ...

Growth lines of primary teeth may help evaluate risk of developing mental disorders

BRISTOL, UK/BOSTON, US: The thickness of growth marks in primary teeth may help identify children at risk for depression and other mental health disorders ...

Henry Schein Cares Foundation opens fund for Ebola relief

MELVILLE, N.Y., USA: Henry Schein Inc. recently opened the Henry Schein Ebola Relief Fund to support relief efforts related to the Ebola outbreak in West ...

Relief group seeks dental assistants for mission to Nicaragua

NEW YORK CITY: International Medical Alliance (IMA), a non-profit group based in Rancho Mirage, Calif., is seeking two registered dental assistants for an ...

A smile for her son

NEW YORK, NY, USA: Jalen’s mother realized that having a beautiful smile would change everything for her son. Accidents resulting in trauma to his ...

Scientists declare CUS an autoimmune disease

NEW YORK, USA/LEIPZIG, Germany: Patients that suffer from a very rare condition affecting the oral mucosa may soon get relief from new research conducted in...

Education

On-demand
webinar

Reaching new levels in bone augmentation using Sculptoss^® Individulized ceramic membrane and GTO^®

Dr. Jonas Anderud Department of Oral and Maxillofacial Surgery, Halmstad, Sweden – Department of Biomaterials, Gothenburg University, Sweden

Dr. Johan Malmström Department of Oral and Maxillofacial Surgery, Halmstad, Sweden – Department of Biomaterials, Gothenburg University, Sweden – Brånemark Clinic Gothenburg, Sweden, Dr. Jonas Anderud Department of Oral and Maxillofacial Surgery, Halmstad, Sweden – Department of Biomaterials, Gothenburg University, Sweden

Watch recording

1CE

Live webinar
Tue. 21 October 2025
7:00 PM EST (New York)